All In Biotech

Drug Trial Radar · NCT02061813

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Abametapir Lotion in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design

Last checked: Nov 20, 2026Latest source record: Jul 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Jan 2014

Primary completion

Jan 2014

Study completion May 2014

Sponsor

Sponsor type
Industry
First posted
Feb 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.

Conditions

  • Head Lice

Interventions

  • Abametapir Lotion 0.74% w/wDrug

    applied 0.2 mL topically under occlusive condition

  • Sodium Lauryl SulfateDrug

    Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.

  • Saline 0.9%Drug

    A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans.Time frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TKL Reserach Inc

    Paramus, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.